Literature DB >> 29404976

An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best?

Barbara S Doumouras1, Douglas S Lee2, Wayne C Levy3, Ana C Alba4.   

Abstract

PURPOSE OF REVIEW: While prediction models incorporating biomarkers are used in heart failure, these have shown wide-ranging discrimination and calibration. This review will discuss externally validated biomarker-based risk models in chronic heart failure patients assessing their quality and relevance to clinical practice. RECENT
FINDINGS: Biomarkers may help in determining prognosis in chronic heart failure patients as they reflect early pathologic processes, even before symptoms or worsening disease. We present the characteristics and describe the performance of 10 externally validated prediction models including at least one biomarker among their predictive factors. Very few models report adequate discrimination and calibration. Some studies evaluated the additional predictive value of adding a biomarker to a model. However, these have not been routinely assessed in subsequent validation studies. New and existing prediction models should include biomarkers, which improve model performance. Ongoing research is needed to assess the performance of models in contemporary patients.

Entities:  

Keywords:  Biomarker; Chronic heart failure; Outpatient; Prediction model; Risk score

Mesh:

Substances:

Year:  2018        PMID: 29404976     DOI: 10.1007/s11897-018-0375-y

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  98 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis.

Authors:  Michael P Hudson; Christopher M O'Connor; Wendy A Gattis; Gudaye Tasissa; Vic Hasselblad; Cathy M Holleman; Laura H Gaulden; Frank Sedor; E Magnus Ohman
Journal:  Am Heart J       Date:  2004-03       Impact factor: 4.749

Review 3.  Troponin elevation in heart failure prevalence, mechanisms, and clinical implications.

Authors:  Robb D Kociol; Peter S Pang; Mihai Gheorghiade; Gregg C Fonarow; Christopher M O'Connor; G Michael Felker
Journal:  J Am Coll Cardiol       Date:  2010-09-28       Impact factor: 24.094

4.  Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model.

Authors:  C Zugck; C Krüger; R Kell; S Körber; D Schellberg; W Kübler; M Haass
Journal:  Eur J Heart Fail       Date:  2001-10       Impact factor: 15.534

Review 5.  Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review.

Authors:  Ana C Alba; Thomas Agoritsas; Milosz Jankowski; Delphine Courvoisier; Stephen D Walter; Gordon H Guyatt; Heather J Ross
Journal:  Circ Heart Fail       Date:  2013-07-25       Impact factor: 8.790

6.  Effectiveness of the relative lymphocyte count to predict one-year mortality in patients with acute heart failure.

Authors:  Julio Núñez; Eduardo Núñez; Gema Miñana; Juan Sanchis; Vicent Bodí; Eva Rumiz; Patricia Palau; Myriam Olivares; Pilar Merlos; Clara Bonanad; Luis Mainar; Angel Llàcer
Journal:  Am J Cardiol       Date:  2011-02-04       Impact factor: 2.778

7.  Development and validation of a clinical index to predict survival after cardiac resynchronisation therapy.

Authors:  F Leyva; P W X Foley; B Stegemann; J A Ward; L L Ng; M P Frenneaux; F Regoli; R E A Smith; A Auricchio
Journal:  Heart       Date:  2009-07-09       Impact factor: 5.994

8.  Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial.

Authors:  Rakesh Sharma; Darrel P Francis; Bertram Pitt; Philip A Poole-Wilson; Andrew J S Coats; Stefan D Anker
Journal:  Eur Heart J       Date:  2004-06       Impact factor: 29.983

9.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.

Authors:  M R Cowie; A D Struthers; D A Wood; A J Coats; S G Thompson; P A Poole-Wilson; G C Sutton
Journal:  Lancet       Date:  1997-11-08       Impact factor: 79.321

10.  Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).

Authors:  Liviu Klein; Barry M Massie; Jeffrey D Leimberger; Christopher M O'Connor; Ileana L Piña; Kirkwood F Adams; Robert M Califf; Mihai Gheorghiade
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

View more
  7 in total

1.  Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.

Authors:  Christopher O'Connor; Mona Fiuzat; Hillary Mulder; Adrian Coles; Tariq Ahmad; Justin A Ezekowitz; Kirkwood F Adams; Ileana L Piña; Kevin J Anstrom; Lawton S Cooper; Daniel B Mark; David J Whellan; James L Januzzi; Eric S Leifer; G Michael Felker
Journal:  Eur J Heart Fail       Date:  2019-03-27       Impact factor: 15.534

2.  UMBRELLA protocol: systematic reviews of multivariable biomarker prognostic models developed to predict clinical outcomes in patients with heart failure.

Authors:  Nikolaos P E Kadoglou; Marialena Trivella; Maria D L A Vazquez-Montes; Thomas P A Debray; Kathryn S Taylor; Benjamin Speich; Nicholas Jones; Gary S Collins; F D R Richard Hobbs; Emmanuella Magriplis; Hugo Maruri-Aguilar; Karel G M Moons; John Parissis; Rafael Perera; Nia Roberts; Clare J Taylor
Journal:  Diagn Progn Res       Date:  2020-08-26

Review 3.  Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making.

Authors:  Imo Ebong; Sula Mazimba; Khadijah Breathett
Journal:  Curr Heart Fail Rep       Date:  2019-12

Review 4.  Hyponatremia in Heart Failure: Pathogenesis and Management.

Authors:  Mario Rodriguez; Marcelo Hernandez; Wisit Cheungpasitporn; Kianoush B Kashani; Iqra Riaz; Janani Rangaswami; Eyal Herzog; Maya Guglin; Chayakrit Krittanawong
Journal:  Curr Cardiol Rev       Date:  2019

5.  The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure.

Authors:  Biyanka Jaltotage; Girish Dwivedi; Daryl Eng Lee Ooi; Gnanadevan Mahadavan
Journal:  Curr Cardiol Rev       Date:  2021

6.  Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure.

Authors:  D O C Lino; I A Freitas; G C Meneses; A M C Martins; E F Daher; J H C Rocha; G B Silva Junior
Journal:  Braz J Med Biol Res       Date:  2019-11-25       Impact factor: 2.590

7.  Clinical Utility and Validation of the Krakow DCM Risk Score-A Prognostic Model Dedicated to Dilated Cardiomyopathy.

Authors:  Ewa Dziewięcka; Mateusz Winiarczyk; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska-Małocha; Matylda Gliniak; Jan Robak; Monika Kaciczak; Przemysław Leszek; Małgorzata Celińska-Spodar; Marcin Dziewięcki; Paweł Rubiś
Journal:  J Pers Med       Date:  2022-02-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.